Connecting Research and Experts with Journalists

• share
• favorite_border

In dementia diseases such as Alzheimer's, incorrectly folded proteins accumulate in the brain. Empa researchers have now resolved a particularly active species of protein fibrils with unprecedented precision. The formation of potentially toxic molecules on the surface of protein fibrils was studied from early to late stages spanning over a period of hours.

• share
• favorite_border

The research team of Dr. Byeongjin Park and Dr. Sang Bok Lee at the Korea Institute of Materials Science (KIMS), has developed the world's first ultra-thin film composite material capable of absorbing over 99% of electromagnetic waves from various frequency bands (such as 5G/6G, WiFi, and autonomous driving radar) using a single material.

• share
• favorite_border

Adults aged 35 to 60 are drinking at unprecedented rates, with those who binge drank in high school reporting more past 30-day high-risk drinking in midlife. And this link may be especially strong for women, according to a study just published in Alcohol: Clinical and Experimental Research Health. These trends are particularly concerning as health conditions, and biological processes common with aging put adults in midlife at greater health risk from alcohol use.

• share
• favorite_border

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.

• share
• favorite_border

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

• share
• favorite_border

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.